Septic shock: new pharmacotherapy options or better trial design?

Bibliography

• Czura CJ. "Merinoff symposium 2010: sepsis"-speaking with one voice. Mol Med 2011;17:2-3
   PubMed Web of Science ®Google Scholar
• Vincent JL, Opal S, Marshall JC, Sepsis definitions: time for change. Lancet 2013; In press
   Google Scholar
• Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care 2010;14:207
   Google Scholar
• Werdan K, Pilz G, Bujdoso O, Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 2007;35:2693-701
   PubMed Web of Science ®Google Scholar
• Kreymann KG, de Heer G, Nierhaus A, Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med 2007;35:2677-85
   PubMed Web of Science ®Google Scholar
• Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2007;35:2686-92
   PubMed Web of Science ®Google Scholar
• Turgeon AF, Hutton B, Fergusson DA, Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 2007;146:193-203
   PubMed Web of Science ®Google Scholar
• Ziegler EJ, Fisher CJ Jr, Sprung CL, Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991;324:429-36
   PubMed Web of Science ®Google Scholar
• McCloskey RV, Straube RC, Sanders C, Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 1994;121:1-5
   PubMed Web of Science ®Google Scholar
• Greenman RL, Schein RM, Martin MA, A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991;266:1097-102
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Sprung CL, Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006;34:344-53
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Tomayko JF, Angus DC, Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009;37:2929-38
   PubMedGoogle Scholar
• Vincent JL, Laterre PF, Cohen J, A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005;23:400-5
   PubMed Web of Science ®Google Scholar
• Cruz DN, Antonelli M, Fumagalli R, Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-52
   PubMed Web of Science ®Google Scholar
• Vincent JL. Sepsis: clearing the blood in sepsis. Nat Rev Nephrol 2009;5:559-60
   PubMed Web of Science ®Google Scholar
• Abraham E, Anzueto A, Gutierrez G, Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock. Lancet 1998;351:929-33
   PubMed Web of Science ®Google Scholar
• Fisher CJ, Dhainaut JF, Opal SM, Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836-43
   PubMed Web of Science ®Google Scholar
• Opal SM, Fisher CJ Jr, Dhainaut JF, Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25:1115-24
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garbino J, Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001;29:503-10
   PubMed Web of Science ®Google Scholar
• Sorensen J, Kald B, Tagesson C, Platelet-activating factor and phospholipase A2 in patients with septic shock and trauma. Intensive Care Med 1994;20:555-61
   PubMedGoogle Scholar
• Dhainaut JF, Tenaillon A, Le Tulzo Y, Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994;22:1720-8
   PubMed Web of Science ®Google Scholar
• Dhainaut JF, Tenaillon A, Hemmer M, Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 sepsis investigator group. Crit Care Med 1998;26:1963-71
   PubMed Web of Science ®Google Scholar
• Opal S, Laterre PF, Abraham E, Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004;32:332-41
   PubMed Web of Science ®Google Scholar
• Sprung CL, Caralis PV, Marcial EH, The effects of high-dose corticosteroids in patients with septic shock. N Engl J Med 1984;311:1137-43
   PubMed Web of Science ®Google Scholar
• The Veterans Administration Systemic Sepsis Cooperative Study Group. effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:659-65
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Troche G, A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-45
   PubMed Web of Science ®Google Scholar
• Annane D, Sebille V, Charpentier C, Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71
   PubMed Web of Science ®Google Scholar
• Vincent JL. Steroids in Sepsis: another swing of the pendulum in our clinical trials. Crit Care 2008;12:141
   PubMedGoogle Scholar
• Sprung CL, Annane D, Keh D, Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008;358:111-24
   PubMed Web of Science ®Google Scholar
• Schortgen F, Clabault K, Katsahian S, Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 2012;185:1088-95
   PubMed Web of Science ®Google Scholar
• Bernard GR, Wheeler AP, Russell JA, The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-18
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Wiedermann CJ, Juers M, Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95:850-6
   PubMed Web of Science ®Google Scholar
• Bernard GR, Vincent JL, Laterre PF, Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
   PubMed Web of Science ®Google Scholar
• Vincent JL, Bernard GR, Beale R, Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE. Crit Care Med 2005;33:2266-77
   PubMed Web of Science ®Google Scholar
• Abraham E, Laterre PF, Garg R, Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41
   PubMed Web of Science ®Google Scholar
• Nadel S, Goldstein B, Williams MD, Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-43
   PubMed Web of Science ®Google Scholar
• Angus DC. Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party. Crit Care 2012;16:107
   PubMedGoogle Scholar
• Kalil AC, LaRosa SP. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 2012;12:678-86
   PubMed Web of Science ®Google Scholar
• Saito H, Maruyama I, Shimazaki S, Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007;5:31-41
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Svoboda P, Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001;29:2081-9
   PubMed Web of Science ®Google Scholar
• Abraham E, Reinhart K, Opal S, Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-47
   PubMed Web of Science ®Google Scholar
• Laterre PF, Opal SM, Abraham E, A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Crit Care 2009;13:R36
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Laterre PF, Francois B, Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183:1561-8
   PubMed Web of Science ®Google Scholar
• Cornet AD, Smit EG, Beishuizen A, The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007;98:579-86
   PubMedGoogle Scholar
• Agarwal R, Gupta D. Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C? Intensive Care Med 2005;31:1297-8
   PubMedGoogle Scholar
• Jaimes F, de la Rosa G, Morales C, Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med 2009;37:1185-96
   PubMed Web of Science ®Google Scholar
• Novack V, Terblanche M, Almog Y. Do statins have a role in preventing or treating sepsis? Crit Care 2006;10:113
   PubMedGoogle Scholar
• Kouroumichakis I, Papanas N, Proikaki S, Statins in prevention and treatment of severe sepsis and septic shock. Eur J Intern Med 2011;22:125-33
   PubMed Web of Science ®Google Scholar
• Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect 2009;15:325-34
   PubMed Web of Science ®Google Scholar
• Dobesh PP, Klepser DG, McGuire TR, Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009;29:621-30
   PubMed Web of Science ®Google Scholar
• Donnino MW, Cocchi MN, Howell M, Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 2009;16:230-4
   PubMed Web of Science ®Google Scholar
• Majumdar SR, McAlister FA, Eurich DT, Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006;333:999
   PubMed Web of Science ®Google Scholar
• Novack V, Eisinger M, Frenkel A, The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009;35:1255-60
   PubMed Web of Science ®Google Scholar
• Kruger PS, Harward ML, Jones MA, Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011;183:774-81
   PubMedGoogle Scholar
• Takala J, Ruokonen E, Webster NR, Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999;341:785-92
   PubMed Web of Science ®Google Scholar
• Lopez A, Lorente JA, Steingrub J, Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004;32:21-30
   PubMed Web of Science ®Google Scholar
• Russell JA, Walley KR, Singer J, Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87
   PubMed Web of Science ®Google Scholar
• Rehberg S, Ertmer C, Vincent JL, Role of selective V1a receptor agonism in ovine septic shock. Crit Care Med 2011;39:119-25
   PubMedGoogle Scholar
• Volk HD, Reinke P, Krausch D, Monocyte deactivation–rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996;22(Suppl 4):S474-81
   PubMedGoogle Scholar
• Docke WD, Randow F, Syrbe U, Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-81
   PubMed Web of Science ®Google Scholar
• Wasserman D, Ioannovich JD, Hinzmann RD, Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 1998;26:434-9
   PubMed Web of Science ®Google Scholar
• Eichacker PQ, Waisman Y, Natanson C, Cardiopulmonary effects of granulocyte colony stimulating factor in a canine model of bacterial peritonitis. J Appl Physiol 1994;77:2366-73
   PubMed Web of Science ®Google Scholar
• O'Reilly M, Silver GM, Greenhalgh DG, Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992;33:679-82
   PubMed Web of Science ®Google Scholar
• Carr R, Brocklehurst P, Dore CJ, Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 2009;373:226-33
   PubMed Web of Science ®Google Scholar
• Meisel C, Schefold JC, Pschowski R, Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-8
   PubMed Web of Science ®Google Scholar
• Bo L, Wang F, Zhu J, Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011;15:R58
   PubMed Web of Science ®Google Scholar
• Warren HS, Amato SF, Fitting C, Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993;177:89-97
   PubMed Web of Science ®Google Scholar
• Vincent JL. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 1997;25:372-4
   PubMed Web of Science ®Google Scholar
• Levy MM, Fink MP, Marshall JC, 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit Care Med 2003;31:1250-6
   PubMed Web of Science ®Google Scholar
• Baudo F, Caimi TM, de CF, Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998;24:336-42
   PubMed Web of Science ®Google Scholar
• Kienast J, Juers M, Wiedermann CJ, Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4:90-7
   PubMed Web of Science ®Google Scholar
• Rivers E, Nguyen B, Havstad S, Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96
   PubMed Web of Science ®Google Scholar
• Pickkers P, Heemskerk S, Schouten J, Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Crit Care 2012;16:R14
   PubMed Web of Science ®Google Scholar